PortalPublikationenSystemic treatment with corticosteroids in psoriasis--health...

Systemic treatment with corticosteroids in psoriasis--health care provision far beyond the S3-guidelines.

Standard

Systemic treatment with corticosteroids in psoriasis--health care provision far beyond the S3-guidelines. / Augustin, Matthias; Schäfer, Ines; Reich, Kristian; Glaeske, Gerd; Radtke, Marc.

in: J DTSCH DERMATOL GES, Jahrgang 9, Nr. 10, 10, 2011, S. 833-838.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Augustin, M, Schäfer, I, Reich, K, Glaeske, G & Radtke, M 2011, 'Systemic treatment with corticosteroids in psoriasis--health care provision far beyond the S3-guidelines.', J DTSCH DERMATOL GES, Jg. 9, Nr. 10, 10, S. 833-838. <http://www.ncbi.nlm.nih.gov/pubmed/21627773?dopt=Citation>

APA

Augustin, M., Schäfer, I., Reich, K., Glaeske, G., & Radtke, M. (2011). Systemic treatment with corticosteroids in psoriasis--health care provision far beyond the S3-guidelines. J DTSCH DERMATOL GES, 9(10), 833-838. [10]. http://www.ncbi.nlm.nih.gov/pubmed/21627773?dopt=Citation

Vancouver

Augustin M, Schäfer I, Reich K, Glaeske G, Radtke M. Systemic treatment with corticosteroids in psoriasis--health care provision far beyond the S3-guidelines. J DTSCH DERMATOL GES. 2011;9(10):833-838. 10.

Bibtex

@article{b8cfde826fb74991bdfe33af7e5255ec,
title = "Systemic treatment with corticosteroids in psoriasis--health care provision far beyond the S3-guidelines.",
abstract = "The basis of induction therapy for psoriasis in Germany is the S3-guideline which for moderate to severe psoriasis recommends the systemic agents fumaric acid esters, methotrexate, cyclosporine and the biologicals infliximab, etanercept, adalimumab and ustekinumab. Systemic glucocorticosteroids (GCS) are not proposed.",
keywords = "Germany, Humans, Male, Female, Administration, Oral, Internal Medicine, Methotrexate/administration & dosage, Adrenal Cortex Hormones/*administration & dosage, Anti-Inflammatory Agents/*administration & dosage, Cyclosporine/therapeutic use, Drug Utilization/statistics & numerical data, Fumarates/therapeutic use, General Practice, *Guideline Adherence, Off-Label Use/*statistics & numerical data, Psoriasis/diagnosis/*drug therapy, Retinoids/therapeutic use, Germany, Humans, Male, Female, Administration, Oral, Internal Medicine, Methotrexate/administration & dosage, Adrenal Cortex Hormones/*administration & dosage, Anti-Inflammatory Agents/*administration & dosage, Cyclosporine/therapeutic use, Drug Utilization/statistics & numerical data, Fumarates/therapeutic use, General Practice, *Guideline Adherence, Off-Label Use/*statistics & numerical data, Psoriasis/diagnosis/*drug therapy, Retinoids/therapeutic use",
author = "Matthias Augustin and Ines Sch{\"a}fer and Kristian Reich and Gerd Glaeske and Marc Radtke",
year = "2011",
language = "English",
volume = "9",
pages = "833--838",
journal = "J DTSCH DERMATOL GES",
issn = "1610-0379",
publisher = "Wiley-Blackwell",
number = "10",

}

RIS

TY - JOUR

T1 - Systemic treatment with corticosteroids in psoriasis--health care provision far beyond the S3-guidelines.

AU - Augustin, Matthias

AU - Schäfer, Ines

AU - Reich, Kristian

AU - Glaeske, Gerd

AU - Radtke, Marc

PY - 2011

Y1 - 2011

N2 - The basis of induction therapy for psoriasis in Germany is the S3-guideline which for moderate to severe psoriasis recommends the systemic agents fumaric acid esters, methotrexate, cyclosporine and the biologicals infliximab, etanercept, adalimumab and ustekinumab. Systemic glucocorticosteroids (GCS) are not proposed.

AB - The basis of induction therapy for psoriasis in Germany is the S3-guideline which for moderate to severe psoriasis recommends the systemic agents fumaric acid esters, methotrexate, cyclosporine and the biologicals infliximab, etanercept, adalimumab and ustekinumab. Systemic glucocorticosteroids (GCS) are not proposed.

KW - Germany

KW - Humans

KW - Male

KW - Female

KW - Administration, Oral

KW - Internal Medicine

KW - Methotrexate/administration & dosage

KW - Adrenal Cortex Hormones/administration & dosage

KW - Anti-Inflammatory Agents/administration & dosage

KW - Cyclosporine/therapeutic use

KW - Drug Utilization/statistics & numerical data

KW - Fumarates/therapeutic use

KW - General Practice

KW - Guideline Adherence

KW - Off-Label Use/statistics & numerical data

KW - Psoriasis/diagnosis/drug therapy

KW - Retinoids/therapeutic use

KW - Germany

KW - Humans

KW - Male

KW - Female

KW - Administration, Oral

KW - Internal Medicine

KW - Methotrexate/administration & dosage

KW - Adrenal Cortex Hormones/administration & dosage

KW - Anti-Inflammatory Agents/administration & dosage

KW - Cyclosporine/therapeutic use

KW - Drug Utilization/statistics & numerical data

KW - Fumarates/therapeutic use

KW - General Practice

KW - Guideline Adherence

KW - Off-Label Use/statistics & numerical data

KW - Psoriasis/diagnosis/drug therapy

KW - Retinoids/therapeutic use

M3 - SCORING: Journal article

VL - 9

SP - 833

EP - 838

JO - J DTSCH DERMATOL GES

JF - J DTSCH DERMATOL GES

SN - 1610-0379

IS - 10

M1 - 10

ER -